Currently out of the existing stock ratings of Leonid Timashev, 160 are a BUY (90.4%), 17 are a HOLD (9.6%).

Leonid Timashev

Work Performance Price Targets & Ratings Chart

Analyst Leonid Timashev, currently employed at RBC, carries an average stock price target met ratio of 47.42% that have a potential upside of 44.63% achieved within 129 days. Previously, Leonid Timashev worked at JEFFERIES.

Leonid Timashev’s has documented 343 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AXSM, Axsome Therapeutics at 07-Jul-2026.

Wall Street Analyst Leonid Timashev

Analyst best performing recommendations are on DSGN (DESIGN THERAPEUTICS).
The best stock recommendation documented was for DSGN (DESIGN THERAPEUTICS) at 3/11/2025. The price target of $5 was fulfilled within 1 day with a profit of $0.33 (6.19%) receiving and performance score of 61.91.

Average potential price target upside

of $57.79 (56.49%) on AXSM (AXSOME THERAPEUTICS).
of $31.78 (30.59%) on RVMD (REVOLUTION MEDICINES).
of $31.28 (71.96%) on CYTK (CYTOKINETICS).

RVMD Revolution Medicines EWTX Edgewise Therapeutics INSM Insmed ALKS Alkermes Plc AXSM Axsome Therapeutics BCYC Bicycle Therapeutics Ltd BHVN Biohaven Pharmaceutical Holding Co Ltd CGON CG Oncology, Common stock CMPS Compass Pathways Plc CRMD CorMedix CYTK Cytokinetics DSGN Design Therapeutics EXEL Exelixis IDYA Ideaya Biosciences JAZZ Jazz Pharmaceuticals PLC LEGN Legend Biotech Corp NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares NUVB Nuvation Bio PYXS Pyxis Oncology VSTM Verastem XNCR Xencor

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Michael Schmidt (GUGGENHEIM)